Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery. This funding will enhance its AI platform and drug discovery capabilities.
Galux, a South Korea-based biotech company, has successfully closed a $29 million Series B financing round. This funding will accelerate the development of next-generation AI for creating therapeutically viable molecules. The round involved both existing and new institutional investors. With this round, Galux's total capital raised increases to $47 million.
Who to call at Galux, and when
A new round usually means Galux is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Galux raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Galux, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Galux. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Galux
Location
Seoul, Seoul, South Korea
About
Galux is a South Korean biotech company that specializes in AI-driven protein therapeutics discovery. The company is focused on developing innovative solutions for precise protein design in therapeutic applications. Its advanced AI platforms aim to tackle challenges in molecular design and optimize the development of targeted therapies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Galux raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SeoulBiotechnologyArtificial Intelligence